Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + Trastuzumab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer; HER2-positive; Metastatic
Conditions
Breast Cancer; HER2-positive; Metastatic
Trial Timeline
Apr 26, 2021 → Dec 30, 2029
NCT ID
NCT04784715About Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + Trastuzumab
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + Trastuzumab is a phase 3 stage product being developed by Daiichi Sankyo for Breast Cancer; HER2-positive; Metastatic. The current trial status is active. This product is registered under clinical trial identifier NCT04784715. Target conditions include Breast Cancer; HER2-positive; Metastatic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04784715 | Phase 3 | Active |
Competing Products
20 competing products in Breast Cancer; HER2-positive; Metastatic